UBA1 and myelodysplastic syndrome: The prognosis of MDS-associated autoimmune disorders remains unclear, as depending on the types of autoimmune disease in each cohort, the impact on survival could be different [7] but we must notice that in our group, despite a high rate of transformation (more than 25%), the twelve death: only one was UBA1 mutated and none of the VEXAS patients transformed into AML.